<DOC>
	<DOCNO>NCT00779480</DOCNO>
	<brief_summary>To determine maximum tolerate dose KW-2449 people acute myelogenous leukemia candidate approve therapy . As well , study determine response rate KW-2449 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic/Pharmacodynamic Study KW-2449 Acute Myelogenous Leukemia ( AML ) ( Protocol Number : 2449-US-002 )</brief_title>
	<detailed_description>Phase 1 : To determine maximum tolerated daily dose ( MTDD ) KW 2449 administer subject AML candidate approve therapy . This originally Phase 1/Phase 2 study . However , tolerable dose potential efficacy could identify Phase 1 . Therefore , Phase 2 never conduct .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Histologically confirm diagnosis AML ( exclude acute promyelocytic leukemia ) relapse responsive prior chemotherapy . Phase 2 : Only subject FLT3/ITD mutation enrol Phase 2 . 2 . Eastern Cooperative Oncology Group ( ECOG ) Scale score17 0 , 1 , 2 ( refer Appendix 1 ) ; 3 . Male female , least 18 year age ; 4 . Signed write informed consent ; 5 . Serum creatinine ≤ 2.0 mg/dL ; 6 . Serum SGOT ( AST ) SGPT ( ALT ) ≤ 5x upper limit normal ( ULN ) ; serum bilirubin ≤ 2 mg/dL ( serum bilirubin must ≤ 3.0 mg/dL subject Gilbert 's Syndrome ) ; 7 . For woman childbearing potential , negative serum pregnancy test must obtain prior administration KW2449 . 1 . Subjects candidate approve therapy underlie condition ; 2 . Prior treatment KW2449 ; 3 . Concomitant treatment chemotherapy ( systemic intrathecal ) , radiotherapy , immunotherapy , investigational agent ; 4 . Evidence active central nervous system ( CNS ) leukemia ; 5 . Previous concurrent malignancy except noninvasive nonmelanomatous skin cancer , situ carcinoma cervix , solid tumor treat curatively , without evidence recurrence least 2 year prior study entry ; 6 . Uncontrolled systemic infection ( viral , bacterial , fungal ) ; 7 . Uncontrolled disseminate intravascular coagulopathy ; 8 . Major surgery within 28 day precede first dose KW2449 ; 9 . Radiotherapy within 28 day precede first dose KW2449 , lack recovery radiotherapyrelated acute adverse event ; 10 . Treatment approve systemic therapy underlie hematologic condition within 14 day first dose KW2449 exception hydroxyurea ( Hydrea® ) leukapheresis hyperleukocytosis and/or thrombocytosis ( see Concomitant Medication Treatment ) , lack recovery adverse event prior systemic therapy . 11 . Treatment another investigational agent within 28 day precede first dose KW2449 , lack recovery adverse event treatment ; 12 . Known positive serology human immunodeficiency virus ( type 1 and/or 2 ) ; 13 . Clinically significant cardiac dysfunction ( New York Heart Association Class 3 4 ) time screen , history myocardial infarction heart failure within 3 month precede first dose KW2449 ; 14 . Chronic Graft versus Host Disease ( GVHD ) exception mild ( Grade 1 ) skin GVHD ; 15 . Phase 1 : ≥ Grade 2 nausea vomit within 7 day precede first dose KW 2449 ; 16 . Active autoimmune disease require immunosuppressive therapy ; 17 . Female subject pregnant breast feeding ; Pregnant woman exclude study embryotoxic potential KW2449 unknown . It know whether KW2449 pass human breast milk . Nursing mother use KW2449 . 18 . Male female subject childbearing potential , unwilling use approve , effective mean contraception accordance institution 's standard ; Pregnancy avoid woman receive KW 2449 female partner men receive KW2449 . All subject receive KW2449 implement appropriate contraceptive method . 19 . Known current drug alcohol abuse ; 20 . Other severe , acute , chronic medical psychiatric condition , laboratory abnormality may compromise safety subject study , affect subject 's ability complete study , interfere interpretation study result ; 21 . Subject judge Investigator inappropriate study participation reason , include inability communicate cooperate Investigator ; 22 . Use hematopoietic growth factor ( i.e. , erythropoietin darbepoetin alfa , filgrastim [ granulocyte colonystimulating factor { GCSF } ] , sargramostim [ granulocytemacrophage colonystimulating factor { GMCSF } ] , thrombopoietic agent ) within 14 day precede first dose KW2449 ; 23 . Monoamine oxidaseB ( MAOB ) aldehyde oxidase ( AOX ) inhibitor within 7 day precede first dose KW2449 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Safety</keyword>
	<keyword>Dose Tolerance</keyword>
	<keyword>Pharmacokinetics/Pharmacodynamics</keyword>
	<keyword>FLT-3</keyword>
</DOC>